Decoy Therapeutics Inc. reported a net loss of $7.59 million for the nine months ended September 30, 2026, compared to a $3.54 million loss in the prior year period, driven by a significant increase in research and development expenses. The company recognized $535,059 in grant revenue during the period and maintains a cash balance of approximately $8.17 million as of September 30, 2026.
Decoy Therapeutics entered into a warrant inducement agreement with an institutional investor for the immediate cash exercise of 1,184,434 Series B Milestone Warrants at a reduced price of $3.25 per share. The transaction generated $3.85 million in gross proceeds and included the issuance of 2,368,868 new unregistered warrants to the holder. Proceeds are intended for working capital and general corporate purposes.
Decoy Therapeutics held a Special Meeting of Stockholders on September 14, 2026, where shareholders approved the issuance of common stock upon the exercise of Series A, B, and C Milestone Warrants. Stockholders also approved an amendment to the Certificate of Incorporation to reduce the number of authorized shares of common stock from 100 million to 90 million.